MedTrace Logo

Characterization of Cytokines Expression During Enterovirus Meningitis in Paediatric Populations.

NCT04711876 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2021-01-15

No results posted yet for this study

Summary

Enteroviruses (EV) are the most frequent cause of acute meningitis in the paediatric population. Detection of enterovirus in cerebrospinal fluid (CSF) specimens by Polymerase Chain Reaction (PCR) is the gold standard diagnostic test. Recently, our laboratory published the BLEDI study which highlighted the interest of detecting EV in the blood of the paediatric population : (i) EV was found in more than a quarter of cases in the blood of infants admitted to hospital with isolated fever and (ii) detection of EV was more frequent in the blood than in CSF in neonates and infants with isolated fever, sepsis or meningitis. However, the pathophysiology of EV infections is poorly understood and little work has been done on the inflammatory response to these infections. In EV meningitis, the inflammatory response has been studied primarily in children infected with enterovirus A71 (EV-A71). Indeed, in these children, inappropriate cytokine secretion (cytokine storm) leads to severe neurological and cardiopulmonary damage, which can progress to death. The study of the inflammatory response during meningitis due to other types of EV remains poorly

The objective of BLEDI-CYTOKINES (ancillary study of the BLEDI study) is to study the inflammatory response during EV meningitis in neonates, infants and children, as assessed by cytokine levels in blood and cerebrospinal fluid, by comparing case-controls from an existing cohort.

Conditions

  • Meningitis Enterovirus

Interventions

BIOLOGICAL

Cytokine level in blood and CSF

Measure of cytokine level

Sponsors & Collaborators

  • Laboratory of virology, National Enterovirus and parechovirus Reference Center, University Hospital of Clermont-Ferrand

    collaborator UNKNOWN

  • University Hospital, Clermont-Ferrand

    lead OTHER

Eligibility

Min Age
1 Day
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04711876 on ClinicalTrials.gov